[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518461":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":40,"responsibleParty":60,"collaborators":25,"id":63,"slug":25,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Chulalongkorn University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Empagliflozin","EXPERIMENTAL","Empagliflozin 10 mg po OD",[13],"Drug: Empagliflozin 10 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":23,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Empagliflozin 10 MG",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Matching placebo containing Lactose content (0.26 gram)",[15],[30],{"name":31,"affiliation":5,"role":32},"Nattachai Srisawat","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Sasipha Tachaboon","CONTACT","6622564000","73305","sasipha.t@chulahospital.org",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Faculty of Medicine, Chulalongkorn University","RECRUITING","Bangkok","Pathumwan","10330","Thailand","TH",{"type":50,"coordinates":51},"Point",[52,53],100.50144,13.75398,{"lat":53,"lon":52},[56],{"name":57,"role":36,"phone":37,"phoneExt":58,"email":59},"Tanat Lertussavavivat","73303","lert.tanat@gmail.com",{"type":32,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Nattachai Srisawat ,M.D.","Professor","100518461",false,"NCT06030843","The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","TREAT-CRS","Inclusion criteria\n\n* Age 18 years or more\n* Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction\n* AKI KDIGO any stage or urine NGAL ≥ 150 ng\u002FmL\n* Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL\n\nExclusion criteria\n\n* Denied to participate in the study\n* Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)\n* Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)\n* Acute coronary syndrome\n* Diagnosed with cause of AKI other than cardiorenal syndrome (eg. sepsis, nephrotoxic, dehydration)\n* Anuria or requiring dialysis or expected to required dialysis within 24 hr\n* Baseline eGFR ≤ 20 ml\u002Fmin\u002F1.73m2 with or without dialysis initiated\n* Heart or kidney transplanted\n* Previously received any SGLT2i in the last 3 months before admission\n* Allergic to any SGLT2i\n* Type 1 diabetes mellitus\n* History of ketoacidosis, including diabetic ketoacidosis\n* Pregnancy\n* Comorbid conditions with an expected survival of less than 1 months such as end-stage liver or heart disease, or uncurable malignancy","ALL","18 Years",{"count":72,"type":73},200,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE2","PHASE3","Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.",[80],"Empagliflozin in Cardiorenal Syndrome Type 1",[9,82,83,84,85],"SGLT2i","Cardiorenal syndrome","ADHF","AKI","2026-06-15",{"date":88,"type":89},"2026-06-16","ACTUAL",{"date":91,"type":89},"2025-03-01",{"date":93,"type":73},"2026-12-31",{"name":5,"class":6},1]